integra lifesciences holdings shares slid nearly 15 tuesday after the medicaltechnology company said it was recalling several products made at its boston plant due to concerns about potential high levels of endotoxins shares of the princeton nj company were recently changing hands at 4360 down more than 14 integra said the recall covers recall surgimend primatrix revize and tissuemend products distributed since 2018 adding that those products account for about 5 of its revenue as a result of the recall and a temporary manufacturing halt at the boston plant integra reduced its secondquarter revenue and earnings guidance the company also warned that while it cant currently estimate the fullyear impact of the issue a manufacturing stoppage through the rest of 2023 could potentially cut revenue by about 60 million and adjusted pershare earnings by 35 cents following the report analysts at citi downgraded integra shares to sell from neutral and cut their price target on the stock to 39 from 59 citing lower earnings and revenue estimates and uncertainty about the remediation timeline for the recall